Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinically Viable Assay for Monitoring Uromodulin Glycosylation.

ABSTRACT: Uromodulin, also known as the Tamm-Horsfall protein or THP, is the most abundant protein excreted in human urine. It is associated with the progression of kidney diseases; therefore, changes in the glycosylation profile of this protein could serve as a potential biomarker for kidney health. The typical glycomics analysis approaches used to quantify uromodulin glycosylation involve time-consuming and tedious glycoprotein isolation and labeling steps, which limit their utility in clinical glycomics assays, where sample throughput is important. Herein, we introduce a radically simplified sample preparation workflow, with direct ESI-MS analysis, enabling the quantification of N-linked glycans that originate from uromodulin. The method omits any glycan labeling steps but includes steps to reduce the salt content of the samples, thereby minimizing ion suppression. The method is effective for quantifying subtle glycosylation differences of uromodulin samples derived from different biological states. As a proof of concept, glycosylation from samples that differ by pregnancy status were shown to be differentiable.

SUBMITTER: Patabandige MW

PROVIDER: S-EPMC8541689 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Development of a Clinically Viable Heroin Vaccine.

Project description:Heroin is a highly abused opioid and incurs a significant detriment to society worldwide. In an effort to expand the limited pharmacotherapy options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive evaluation of hapten structure, carrier protein, adjuvant and dosing. Immunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin "immunoantagonism", reducing heroin potency by >15-fold. Moreover, the vaccine effects proved to be durable, persisting for over eight months. The lead vaccine was effective in rhesus monkeys, generating significant and sustained antidrug IgG titers in each subject. Characterization of both mouse and monkey antiheroin antibodies by surface plasmon resonance (SPR) revealed low nanomolar antiserum affinity for the key heroin metabolite, 6-acetylmorphine (6AM), with minimal cross reactivity to clinically used opioids. Following a series of heroin challenges over six months in vaccinated monkeys, drug-sequestering antibodies caused marked attenuation of heroin potency (>4-fold) in a schedule-controlled responding (SCR) behavioral assay. Overall, these preclinical results provide an empirical foundation supporting the further evaluation and potential clinical utility of an effective heroin vaccine in treating opioid use disorders.

| S-EPMC5612493 | biostudies-literature

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring

Project description:Development of a cost-effective and practical targeted transcriptional fingerprinting assay (TFA) for monitoring a diverse repertoire of immune responses identified in the human blood transcriptome relying on a modular transcriptional repertoire built on the basis of variations in transcript abundance measured on a genome wide scale in the blood of nearly 1000 subjects across 16 immunologic conditions.

2020-06-16 | GSE100150 | GEO

Laparoscopic stereoscopic augmented reality: toward a clinically viable electromagnetic tracking solution.

Project description:The purpose of this work was to develop a clinically viable laparoscopic augmented reality (AR) system employing stereoscopic (3-D) vision, laparoscopic ultrasound (LUS), and electromagnetic (EM) tracking to achieve image registration. We investigated clinically feasible solutions to mount the EM sensors on the 3-D laparoscope and the LUS probe. This led to a solution of integrating an externally attached EM sensor near the imaging tip of the LUS probe, only slightly increasing the overall diameter of the probe. Likewise, a solution for mounting an EM sensor on the handle of the 3-D laparoscope was proposed. The spatial image-to-video registration accuracy of the AR system was measured to be [Formula: see text] and [Formula: see text] for the left- and right-eye channels, respectively. The AR system contributed 58-ms latency to stereoscopic visualization. We further performed an animal experiment to demonstrate the use of the system as a visualization approach for laparoscopic procedures. In conclusion, we have developed an integrated, compact, and EM tracking-based stereoscopic AR visualization system, which has the potential for clinical use. The system has been demonstrated to achieve clinically acceptable accuracy and latency. This work is a critical step toward clinical translation of AR visualization for laparoscopic procedures.

| S-EPMC5054216 | biostudies-literature

Microfluidic platform for monitoring Saccharomyces cerevisiae mutation accumulation assay

Project description:Saccharomyces cerevisiae wildtype (YPH) and ung1-deleted strains were cultivated in mutation accumulation experiments over several bottlenecks (0-50-100-150). Two different cutlure systems were used either (i) using random colony selection and plating on petri dish (classical); or (ii) a microfluidic-based system (microfluidic)

2021-08-01 | E-MTAB-10259 | biostudies-arrayexpress

Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.

Project description:Botulinum neurotoxins (BoNT) are the most potent toxins known and a significant bioterrorist threat. Few small molecule compounds have been identified that are active in cell-based or animal models, potentially due to toxin enzyme plasticity. Here we screened commercially available quinolinols, as well as synthesized hydroxyquinolines. Seventy-two compounds had IC50 values below 10 ?M, with the best compound exhibiting submicromolar inhibition (IC50 = 0.8 ?M). Structure-activity relationship trends showed that the enzyme tolerates various substitutions at R1 but has a clear preference for bulky aryl amide groups at R2, while methylation at R3 increased inhibitor potency. Evaluation of the most potent compounds in an ADME panel showed that these compounds possess poor solubility at pH 6.8, but display excellent solubility at low pH, suggesting that oral dosing may be possible. Our data show the potential of quinolinol compounds as BoNT therapeutics due to their good in vitro potencies and favorable ADME properties.

| S-EPMC3983388 | biostudies-literature

A clinically viable approach to restoring visual function using optogenetic gene therapy.

Project description:Optogenetic gene therapies offer a promising strategy for restoring vision to patients with retinal degenerative diseases, such as retinitis pigmentosa (RP). Several clinical trials have begun in this area using different vectors and optogenetic proteins (Clinical Identifiers: NCT02556736, NCT03326336, NCT04945772, and NCT04278131). Here we present preclinical efficacy and safety data for the NCT04278131 trial, which uses an AAV2 vector and Chronos as the optogenetic protein. Efficacy was assessed in mice in a dose-dependent manner using electroretinograms (ERGs). Safety was assessed in rats, nonhuman primates, and mice, using several tests, including immunohistochemical analyses and cell counts (rats), electroretinograms (nonhuman primates), and ocular toxicology assays (mice). The results showed that Chronos-expressing vectors were efficacious over a broad range of vector doses and stimulating light intensities, and were well tolerated: no test article-related findings were observed in the anatomical and electrophysiological assays performed.

| S-EPMC10213293 | biostudies-literature

Clinically viable magnetic poly(lactide-co-glycolide) particles for MRI-based cell tracking.

Project description:To design, fabricate, characterize, and in vivo assay clinically viable magnetic particles for MRI-based cell tracking.Poly(lactide-co-glycolide) (PLGA) encapsulated magnetic nano and microparticles were fabricated. Multiple biologically relevant experiments were performed to assess cell viability, cellular performance, and stem cell differentiation. In vivo MRI experiments were performed to separately test cell transplantation and cell migration paradigms, as well as in vivo biodegradation.Highly magnetic nano (?100 nm) and microparticles (?1-2 µm) were fabricated. Magnetic cell labeling in culture occurred rapidly achieving 3-50 pg Fe/cell at 3 h for different particles types, and >100 pg Fe/cell after 10 h, without the requirement of a transfection agent, and with no effect on cell viability. The capability of magnetically labeled mesenchymal or neural stem cells to differentiate down multiple lineages, or for magnetically labeled immune cells to release cytokines following stimulation, was uncompromised. An in vivo biodegradation study revealed that NPs degraded ?80% over the course of 12 weeks. MRI detected as few as 10 magnetically labeled cells, transplanted into the brains of rats. Also, these particles enabled the in vivo monitoring of endogenous neural progenitor cell migration in rat brains over 2 weeks.The robust MRI properties and benign safety profile of these particles make them promising candidates for clinical translation for MRI-based cell tracking.

| S-EPMC4336220 | biostudies-literature

Relevance of time-dependence for clinically viable diffusion imaging of the spinal cord.

Project description:PurposeTime-dependence is a key feature of the diffusion-weighted (DW) signal, knowledge of which informs biophysical modelling. Here, we study time-dependence in the human spinal cord, as its axonal structure is specific and different from the brain.MethodsWe run Monte Carlo simulations using a synthetic model of spinal cord white matter (WM) (large axons), and of brain WM (smaller axons). Furthermore, we study clinically feasible multi-shell DW scans of the cervical spinal cord (b = 0; b = 711 s mm-2 ; b = 2855 s mm-2 ), obtained using three diffusion times (Δ of 29, 52 and 76 ms) from three volunteers.ResultsBoth intra-/extra-axonal perpendicular diffusivities and kurtosis excess show time-dependence in our synthetic spinal cord model. This time-dependence is reflected mostly in the intra-axonal perpendicular DW signal, which also exhibits strong decay, unlike our brain model. Time-dependence of the total DW signal appears detectable in the presence of noise in our synthetic spinal cord model, but not in the brain. In WM in vivo, we observe time-dependent macroscopic and microscopic diffusivities and diffusion kurtosis, NODDI and two-compartment SMT metrics. Accounting for large axon calibers improves fitting of multi-compartment models to a minor extent.ConclusionsTime-dependence of clinically viable DW MRI metrics can be detected in vivo in spinal cord WM, thus providing new opportunities for the non-invasive estimation of microstructural properties. The time-dependence of the perpendicular DW signal may feature strong intra-axonal contributions due to large spinal axon caliber. Hence, a popular model known as "stick" (zero-radius cylinder) may be sub-optimal to describe signals from the largest spinal axons.

| S-EPMC6586052 | biostudies-literature

Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.

Project description:Novel tricyclic analogues were designed, synthesized, and evaluated as RORγt inverse agonists. Several of these compounds were potent in an IL-17 human whole blood assay and exhibited excellent oral bioavailability in mouse pharmacokinetic studies. This led to the identification of compound 5, which displayed dose-dependent inhibition of IL-17F production in a mouse IL-2/IL-23 stimulated pharmacodynamic model. In addition, compound 5 was studied in mouse acanthosis and imiquimod-induced models of skin inflammation, where it demonstrated robust efficacy comparable to a positive control. As a result of this excellent overall profile, compound 5 (BMS-986251) was selected as a clinically viable developmental candidate.

| S-EPMC7294715 | biostudies-literature

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring (SLE Datasets)

2020-06-16 | GSE100163 | GEO